2025年跨国药企在华高管变动:洞察行业变革新趋势

中国制药网
Jun 30

2025 年以来,全球医药行业格局风云变幻, 强生 、默沙东、诺和诺德、诺华等跨国药企在中国市场的高管职位频繁变动,引发了业界的广泛关注。这些变动不仅反映了企业内部战略的调整,也折射出 中国医药 市场在政策、竞争和创新等多方面因素影响下的深刻变革。今年 4 月,强生中国区主席宋为群宣布离任,7 月由周敏涛接任中国区总裁。同时,自 3 月 1 日起,强生创新制药中国进行架构调整,陈建担任商业运营与...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10